A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Cabazitaxel (Primary) ; Carboplatin (Primary) ; Ipilimumab (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DynaMO
- 10 Jun 2017 Biomarkers information updated
- 19 May 2016 Planned primary completion date changed from 1 Jun 2020 to 1 May 2020.
- 19 May 2016 Status changed from not yet recruiting to recruiting.